Beam Therapeutics Inc
BEAM20.010USD
+0.130+0.65%
Close 07/03, 13:00（ET）Quotes delayed by 15 min
2.01BMarket Cap
LossP/E TTM
More Details of Beam Therapeutics Inc Company
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).
Company Info
Ticker SymbolBEAM
Company nameBeam Therapeutics Inc
IPO dateFeb 06, 2020
Founded at2017
CEOMr. John M. Evans
Number of employees483
Security typeOrdinary Share
Fiscal year-endFeb 06
Address238 Main Street
CityCAMBRIDGE
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code02142
Phone18573278775
Websitehttps://beamtx.com/
Ticker SymbolBEAM
IPO dateFeb 06, 2020
Founded at2017
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Giuseppe Ciaramella, Ph.D.
Dr. Giuseppe Ciaramella, Ph.D.
President
President
107.78K
-6.45%
Dr. Amy Simon, M.D.
Dr. Amy Simon, M.D.
Chief Medical Officer
Chief Medical Officer
1.74K
-97.47%
Dr. Christine P. Bellon, Ph.D.
Dr. Christine P. Bellon, Ph.D.
Chief Legal Officer and Secretary
Chief Legal Officer and Secretary
--
--
Mr. Sravan K. Emany
Mr. Sravan K. Emany
Chief Financial and Principal Financial Officer
Chief Financial and Principal Financial Officer
--
--
Mr. John M. Evans
Mr. John M. Evans
Chief Executive Officer, Principal Accounting Officer, Director
Chief Executive Officer, Principal Accounting Officer, Director
--
--
Mr. Chirfi Guindo
Mr. Chirfi Guindo
Independent Director
Independent Director
--
--
Ms. Christi Shaw
Ms. Christi Shaw
Independent Director
Independent Director
--
--
Dr. John Maraganore, Ph.D.
Dr. John Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Dr. Mark C. Fishman, M.D.
Dr. Mark C. Fishman, M.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Graham K. Cooper
Mr. Graham K. Cooper
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Giuseppe Ciaramella, Ph.D.
Dr. Giuseppe Ciaramella, Ph.D.
President
President
107.78K
-6.45%
Dr. Amy Simon, M.D.
Dr. Amy Simon, M.D.
Chief Medical Officer
Chief Medical Officer
1.74K
-97.47%
Dr. Christine P. Bellon, Ph.D.
Dr. Christine P. Bellon, Ph.D.
Chief Legal Officer and Secretary
Chief Legal Officer and Secretary
--
--
Mr. Sravan K. Emany
Mr. Sravan K. Emany
Chief Financial and Principal Financial Officer
Chief Financial and Principal Financial Officer
--
--
Mr. John M. Evans
Mr. John M. Evans
Chief Executive Officer, Principal Accounting Officer, Director
Chief Executive Officer, Principal Accounting Officer, Director
--
--
Mr. Chirfi Guindo
Mr. Chirfi Guindo
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
No Data
By RegionUSD
Name
Revenue
Proportion
United States
7.47M
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, May 16
Updated: Fri, May 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Farallon Capital Management, L.L.C.
9.87%
The Vanguard Group, Inc.
8.80%
ARK Investment Management LLC
8.43%
Fidelity Management & Research Company LLC
7.56%
BlackRock Institutional Trust Company, N.A.
6.72%
Other
58.61%
Shareholders
Shareholders
Proportion
Farallon Capital Management, L.L.C.
9.87%
The Vanguard Group, Inc.
8.80%
ARK Investment Management LLC
8.43%
Fidelity Management & Research Company LLC
7.56%
BlackRock Institutional Trust Company, N.A.
6.72%
Other
58.61%
Shareholder Types
Shareholders
Proportion
Investment Advisor
38.62%
Investment Advisor/Hedge Fund
29.38%
Hedge Fund
20.30%
Venture Capital
4.83%
Research Firm
2.23%
Sovereign Wealth Fund
1.82%
Individual Investor
1.28%
Bank and Trust
0.46%
Pension Fund
0.31%
Other
0.77%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
531
99.92M
99.37%
+13.13M
2025Q1
562
100.13M
99.59%
+12.37M
2024Q4
542
80.18M
95.83%
-6.23M
2024Q3
539
78.60M
95.42%
-7.95M
2024Q2
538
78.23M
95.09%
-5.21M
2024Q1
550
76.09M
93.23%
-4.97M
2023Q4
549
75.48M
92.79%
-3.23M
2023Q3
554
74.84M
95.14%
-3.35M
2023Q2
566
72.06M
94.81%
-2.24M
2023Q1
583
68.81M
92.54%
-724.80K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Farallon Capital Management, L.L.C.
9.93M
9.87%
+1.69M
+20.50%
Mar 31, 2025
The Vanguard Group, Inc.
8.85M
8.8%
+1.24M
+16.36%
Mar 31, 2025
ARK Investment Management LLC
8.48M
8.43%
+1.41M
+19.98%
Mar 31, 2025
Fidelity Management & Research Company LLC
7.60M
7.56%
+4.49M
+144.60%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
6.76M
6.72%
+838.01K
+14.15%
Mar 31, 2025
ARCH Venture Partners
4.54M
4.51%
--
--
Mar 31, 2025
Nikko Asset Management Co., Ltd.
4.27M
4.24%
+309.26K
+7.81%
Mar 31, 2025
State Street Global Advisors (US)
3.44M
3.42%
+362.74K
+11.79%
Mar 31, 2025
T. Rowe Price Associates, Inc.
2.94M
2.93%
+1.27M
+75.83%
Mar 31, 2025
Kynam Capital Management LP
2.52M
2.5%
+762.01K
+43.39%
Mar 31, 2025
View more
Related ETFs
Updated: Wed, Jul 2
Updated: Wed, Jul 2
Name
Proportion
ARK Genomic Revolution ETF
3.47%
Global X Genomics & Biotechnology ETF
1.9%
WisdomTree BioRevolution Fund
1.65%
ARK Innovation ETF
1.6%
Virtus LifeSci Biotech Clinical Trials ETF
0.65%
Franklin Genomic Advancements ETF
0.61%
SPDR S&P Biotech ETF
0.47%
NYLI Healthy Hearts ETF
0.33%
Direxion Daily S&P Biotech Bull 3X Shares
0.28%
iShares Health Innovation Active ETF
0.17%
View more
ARK Genomic Revolution ETF
Proportion3.47%
Global X Genomics & Biotechnology ETF
Proportion1.9%
WisdomTree BioRevolution Fund
Proportion1.65%
ARK Innovation ETF
Proportion1.6%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.65%
Franklin Genomic Advancements ETF
Proportion0.61%
SPDR S&P Biotech ETF
Proportion0.47%
NYLI Healthy Hearts ETF
Proportion0.33%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.28%
iShares Health Innovation Active ETF
Proportion0.17%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
